<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03189511</url>
  </required_header>
  <id_info>
    <org_study_id>FluvaBAT</org_study_id>
    <nct_id>NCT03189511</nct_id>
  </id_info>
  <brief_title>Effect of Fluvastatin on Brown Fat Activity</brief_title>
  <acronym>FluvaBAT</acronym>
  <official_title>Short Term Effect of Fluvastatin on Brown Adipose Tissue Thermogenesis and Activity in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Irene Burger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to elucidate the effects of Fluvastatin on brown adipose tissue
      activity in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Statins, inhibitors of cholesterol biosynthesis, act by inhibiting the enzyme of the
      mevalonate pathway. Although the clinical benefits of statins are undisputable, they have
      been shown to increase insulin resistance and incidence of type 2 diabetes mellitus, the
      mechanism of which is currently not clear.

      The main function of brown adipose tissue (BAT) is non-shivering thermogenesis (i.e. heat
      production through energy dissipation) in brown adipocytes. There has been a growing interest
      in BAT as a novel therapeutic approach to increase energy expenditure in order to facilitate
      weight-loss and increase insulin sensitivity.

      BAT activity will be assessed using calorimetric test and [18F]-Fluorodeoxyglucose (FDG)
      positron emission tomography (PET).

      We speculate that statins inhibit BAT function and that this mechanism may contribute to the
      above mentioned increase in insulin resistance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2017</start_date>
  <completion_date type="Anticipated">May 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open-label non-randomized historic control (before-after) trial</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(18)F-FDG uptake in the supraclavicular brown adipose tissue measured by PET by the maximum standardized uptake value (SUVmax)</measure>
    <time_frame>14 days</time_frame>
    <description>Cold and Mirabegron induced 18F-FDG uptake into the supra-clavicular brown adipose tissue (scBAT) as determined by 18F-FDG PET/MR standardized uptake value (SUVmax) after two weeks of treatment with Fluvastatin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean standardized uptake value for 18F-FDG uptake (SUVmean) in the supraclavicular adipose tissue depot</measure>
    <time_frame>14 days</time_frame>
    <description>SUVmean in the supraclavicular adipose tissue depot (analog. SUVmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of supraclavicular BAT</measure>
    <time_frame>14 days</time_frame>
    <description>Volume of supraclavicular BAT as determined on Magnetic Resonance Imaging (MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fat fraction with T2 relaxation time of the BAT depot</measure>
    <time_frame>14 days</time_frame>
    <description>fat fraction with T2 relaxation time of the scBAT depot as determined by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold induced thermogenesis</measure>
    <time_frame>14 days</time_frame>
    <description>Cold induced thermogenesis: Increase in energy expenditure above resting metabolic rate in response to a mild cold stimulus and pharmacologic stimulation with Mirabegron.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supraclavicular skin temperature in response to mild cold stimulus</measure>
    <time_frame>14 days</time_frame>
    <description>Supraclavicular skin temperature in response to mild cold stimulus measured by local probe</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Adipose Tissue, Brown</condition>
  <condition>Insulin Resistance</condition>
  <condition>Clinical Trial</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers receive calorimetric tests and FDG PET scans pre and post 2 weeks of Fluvastatine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvastatin</intervention_name>
    <description>Fluvastatin 40 mg twice daily per mouth for 14 days.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Lescol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male volunteers (18-40 y)

          -  body mass index 19 to 27 kg/m²

          -  Fluent in German or English

        Exclusion Criteria:

          -  Regular physical exercise of more than &gt;150 min of exercise per week.

          -  Contraindications to the class of drugs under study, e.g. known hypersensitivity or
             allergy to class of drugs or the investigational product,

          -  Other clinically significant concomitant disease states (e.g., renal failure, hepatic
             dysfunction, cardiovascular disease, etc.),

          -  Clinically indicated intake of the following medications: Corticosteroids,
             CYP3A4-Inhibitors (Itraconazol, Voriconazol, Fluconazol, Clarithromycin, Erythromycin,
             Indinavir, Nelfinavir, Ritonavir, Grapefruit juice), Beta-Blocker, Neuroleptics,
             Tricyclic Antidepressants,

          -  Known or suspected non-compliance, drug or alcohol abuse,

          -  Inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, dementia, etc. of the participant,

          -  Participation in another study with investigational drug within the 30 days preceding
             and during the present study,

          -  Participation in another study involving ionizing radiation in the same year,

          -  Previous enrolment into the current study,

          -  Enrolment of the investigator, his/her family members, employees and other dependent
             persons,

          -  MRI contraindications: Not MRI-compatible metal in the body, cardiac pacemaker,
             History of surgery with possible metal clips/parts still in the body, claustrophobia.

          -  Resting pulse rate &gt; 70 bpm

          -  Known arterial hypertension or resting blood pressure &gt; 130/80 mmHg.

          -  frequence corrected QT-time (QTc) &gt;430 ms

          -  Serum creatinine &gt; 1.5x upper limit of norm (ULN), i.e.&gt; 145 µmol/L

          -  creatine kinase &gt; 1.5x ULN, i.e. &gt; 300 U/L

          -  aspartate transaminase (ASAT) &gt; 1.5x ULN, i.e. &gt; 51 U/L

          -  alanine aminotransferase (ALAT) &gt; 1.5x ULN, i.e. &gt; 88 U/L

          -  Hypothyroidism

          -  Vitamin D deficiency, Vitamin D3 &lt; 25 nmol/L

          -  Intake of anticoagulants or inhibitors of platelet aggregation (e.g. Aspirin,
             clopidogrel).

          -  Known tendency to form keloids (hypertrophic scar tissue)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene A Burger, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irene A Burger, M.D.</last_name>
    <phone>+41 44 255 11 64</phone>
    <email>irene.burger@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthias Betz, M.D.</last_name>
    <phone>+41 61 55 65654</phone>
    <email>matthias.betz@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Zurich, PET/MR Center</name>
      <address>
        <city>Schlieren</city>
        <state>Zurich</state>
        <zip>8952</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene A Burger, M.D.</last_name>
      <phone>+41 44 255 11 64</phone>
      <email>irene.burger@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Anton S Becker, M.D.</last_name>
      <phone>+41 44 255 11 11</phone>
      <email>anton.becker@usz.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital of Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Betz, M.D.</last_name>
      <phone>+41 61 55 65654</phone>
      <email>matthias.betz@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Gani Gashi, M.D.</last_name>
      <phone>+41 61 3286375</phone>
      <email>Gani.Gashi@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Claudia Maushart, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Cypess AM, Weiner LS, Roberts-Toler C, Franquet Elía E, Kessler SH, Kahn PA, English J, Chatman K, Trauger SA, Doria A, Kolodny GM. Activation of human brown adipose tissue by a β3-adrenergic receptor agonist. Cell Metab. 2015 Jan 6;21(1):33-8. doi: 10.1016/j.cmet.2014.12.009.</citation>
    <PMID>25565203</PMID>
  </reference>
  <reference>
    <citation>Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22;305(24):2556-64. doi: 10.1001/jama.2011.860.</citation>
    <PMID>21693744</PMID>
  </reference>
  <reference>
    <citation>Puurunen J, Piltonen T, Puukka K, Ruokonen A, Savolainen MJ, Bloigu R, Morin-Papunen L, Tapanainen JS. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2013 Dec;98(12):4798-807. doi: 10.1210/jc.2013-2674. Epub 2013 Oct 23.</citation>
    <PMID>24152688</PMID>
  </reference>
  <reference>
    <citation>Duvnjak L, Blaslov K. Statin treatment is associated with insulin sensitivity decrease in type 1 diabetes mellitus: A prospective, observational 56-month follow-up study. J Clin Lipidol. 2016 Jul-Aug;10(4):1004-1010. doi: 10.1016/j.jacl.2016.04.012. Epub 2016 May 10.</citation>
    <PMID>27578133</PMID>
  </reference>
  <reference>
    <citation>Chapple CR, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele JJ, Bosman B, Boerrigter P, Drogendijk T, Ridder A, Van Der Putten-Slob I, Yamaguchi O; Dragon Investigator Group. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013 Sep;24(9):1447-58. doi: 10.1007/s00192-013-2042-x. Epub 2013 Mar 8.</citation>
    <PMID>23471546</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Zurich</investigator_affiliation>
    <investigator_full_name>Irene Burger</investigator_full_name>
    <investigator_title>Head of PET/CT center</investigator_title>
  </responsible_party>
  <keyword>Brown Adipose Tissue</keyword>
  <keyword>Brown Fat</keyword>
  <keyword>Fluvastatin</keyword>
  <keyword>Prospective Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

